Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.87 CHF | -0.20% | -0.08% | +4.71% |
Sales 2024 * | 48.85B 44.52B | Sales 2025 * | 50.66B 46.17B | Capitalization | 198B 181B |
---|---|---|---|---|---|
Net income 2024 * | 10.22B 9.31B | Net income 2025 * | 11.93B 10.87B | EV / Sales 2024 * | 4.32 x |
Net Debt 2024 * | 12.78B 11.65B | Net Debt 2025 * | 11.31B 10.3B | EV / Sales 2025 * | 4.14 x |
P/E ratio 2024 * |
19.2
x | P/E ratio 2025 * |
16.6
x | Employees | 76,057 |
Yield 2024 * |
3.71% | Yield 2025 * |
3.85% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | -0.29% | ||
1 week | -0.08% | ||
Current month | +1.72% | ||
1 month | +3.70% | ||
3 months | -4.02% | ||
6 months | +5.01% | ||
Current year | +4.71% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +3.01% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 88.87 | -0.20% | 2 892 166 |
24-04-30 | 89.05 | +0.20% | 2,925,672 |
24-04-29 | 88.87 | -0.70% | 2,820,456 |
24-04-26 | 89.5 | -0.56% | 3,249,537 |
24-04-25 | 90 | +0.99% | 4,571,037 |
Delayed Quote Swiss Exchange, May 02, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.71% | 198B | |
+30.28% | 699B | |
+25.07% | 571B | |
-4.70% | 364B | |
+18.04% | 326B | |
+2.79% | 286B | |
+14.68% | 236B | |
-12.43% | 194B | |
-3.42% | 154B | |
-4.28% | 149B |
- Stock Market
- Equities
- NOVN Stock